Based on the forecasted data, antihypertensive medicine sales in Türkiye are expected to grow consistently from 192.4 million New Turkish Liras in 2024 to 293.3 million New Turkish Liras in 2028. The year-on-year variations are as follows:
- 2024 to 2025: 13.19%
- 2025 to 2026: 11.61%
- 2026 to 2027: 10.33%
- 2027 to 2028: 9.34%
The compound annual growth rate (CAGR) over the five-year period from 2024 to 2028 is approximately 11.18%.
Future trends to watch include the impact of evolving healthcare policies, economic factors, and advancements in hypertensive treatments. Additionally, demographic changes and increasing awareness about hypertension management are likely to influence sales positively.
